Israel - English - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 3000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxalta uk ltd - octocog alfa - powder and solvent for solution for injection - 250unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxalta uk ltd - octocog alfa - powder and solvent for solution for injection - 500unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxalta uk ltd - octocog alfa - powder and solvent for solution for injection - 1000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxalta uk ltd - octocog alfa - powder and solvent for solution for infusion - 1500unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxalta uk ltd - octocog alfa - powder and solvent for solution for injection - 2000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxalta uk ltd - octocog alfa - powder and solvent for solution for infusion - 3000unit

Israel - English - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 250 iu/vial - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.